Illumina found customers for its gene sequencing technology and data services at genomic research centers, clinical research organizations, research institutions, and biotech and pharmaceutical companies. "They're providing you real-time guidance on the impact of your "foodprint" as they call it, on your glucose behavior," said Annika Jimenez, senior vice president for data at San Diego's DexCom (NASDAQ: DXCM), which specializes in continuous glucose monitoring technology for managing diabetes. Navid Alipour, a co-founder and managing partner of San Diego's Analytics Ventures, said his firm's portfolio company CureMatch is taking a direct-to-consumer approach, in which cancer patients pay CureMatch to recommend the top three combinations of chemotherapy drugs for each patient's cancer. CureMetrix, another company in Analytics Ventures' portfolio, uses machine learning to analyze mammography images for breast cancer--and must still get FDA approval before it can be used in the United States, Alipour said.
The company will also increase commercialization efforts in France, Germany, the U.K., Asia and the Middle East, and further development efforts in data analytics and artificial intelligence to provide personalized insights that drive meaningful behavior change. Glooko provides payers, employers, pharmaceutical companies and health systems with a diabetes digital health platform that delivers personalized and actionable insights to people with diabetes and their care teams that aim to drive improved outcomes at a lower cost. "With this capital, we will accelerate our investments in clinical solutions that aim to increase medication adherence, provide personalized insights and prompts that drive behavior change for people with diabetes, and deliver clinical decision support to thousands of clinicians and coaches so they can better support people with diabetes in between office visits." Georgian Partners is a thesis-driven growth equity firm investing in SaaS-based business software companies exploiting applied artificial intelligence, security first and conversational business.
It affects around 29 million Americans, and is caused by high blood sugar levels, often the result of poor diet and exercise. Blurred vision is also a common early sign of type 2 diabetes. At first, it can be hard for the body to adapt to changes in blood sugar, and as a result blurred vision is common during the early stages of diabetes. After the body gets used to new higher blood sugar levels, vision will return to normal.
Eric Williams, VP of Data Science & Analytics at Omada Health provided a view into how his digital therapeutics company is combining AI with human intelligence to help pre-diabetic patients lose weight. Williams provided these insights during the Interop ITX session, Where Artificial Intelligence Meets Human Intelligence: Building Digital Healthcare for the Future. To help companies and insurers help patients make the behavioral changes necessary to prevent diabetes, Omada provides a "Symphony" of tools that include scales, wearables, and a food-tracking app. As part of its evolution, Omada sought to complement its health coaches with digital health coaches.
Scientists from Harvard and the University of Vermont developed a machine learning tool -- a type of AI that enables computers to learn without being explicitly programmed -- to better identify depression by studying Instagram posts, suggesting "new avenues for early screening and detection of mental illness." NYU researchers analyzed medical and lab records to accurately predict the onset of dozens of diseases and conditions including Type 2 diabetes, heart or kidney failure and stroke. When IBM's Watson computing system won the TV game show "Jeopardy" in 2011, "there were a lot of folks in health care who said that is the same process doctors use when they try to understand health care," said Anil Jain, chief medical officer of Watson Health. Research firm CB Insights this year identified 106 digital health startups applying machine learning and predictive analytics "to reduce drug discovery times, provide virtual assistance to patients, and diagnose ailments by processing medical images."
India's largest eye care provider, Aravind Eye Hospital, has been quietly working for over four years with Google on a project to use artificial intelligence (AI) in ophthalmology. "With AI, we will be able to grade diabetic retinopathy to a certain level of identification, mainly for screening" -- Dr R Kim, chief medical officer at Aravind Eye Hospital "With AI, we will be able to grade diabetic retinopathy to a certain level of identification, mainly for screening. It will be seen at a patient care level, a diabetes management level," said Anand Sivaraman, director of Bengaluru-based Remidio, maker of a smartphone-based ophthalmic imaging system. It will be seen at a patient care level, a diabetes management level" -- Anand Sivaraman, director, Remidio However, Sivaraman said the challenge lies in making sure there are no false negatives, which could deprive patients of treatment or consultation.
"We can no longer be a'wait and see' industry," D'Avolio said. "Instead we're pulling real insights from disparate data sources and using these to inform clinical care. We're thrilled to partner with these leading institutions to serve such a critical patient population, and believe that the work this new learning health system will accomplish could fundamentally change how we care for people with T1D and their families."
Children's Mercy is advancing care for children with diabetes through the Children's Mercy Diabetes Center by providing comprehensive care for children as well as support and resources for family members. About Joslin Diabetes Center Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S. About Cyft Based in Cambridge, Mass., Cyft partners with leading care organizations to identify opportunities to optimize care management efforts for chronic / complex, behavioral health, and dual-eligible populations. About the Helmsley Charitable Trust The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting effective organizations in health and select place-based initiatives.
Apple, Google and Amazon have announced or are reported to be developing cutting-edge technologies for managing diabetes, one of the fastest-growing chronic illnesses, affecting more than 420 million people worldwide. The latest diabetes-related tech endeavor to be announced is the Alexa Diabetes Challenge, which focuses on finding ways for the Amazon Echo smart speaker -- and its Alexa digital assistant -- to assist people with Type 2 diabetes in living healthier lives. CNBC reported last month that Apple Chief Executive Tim Cook was spotted "wearing a prototype glucose-tracker" with his Apple Watch. The global market for diabetes care will be worth $35.5 billion by 2024, according to Grand View Research, and this represents a natural business opportunity for anyone in the information technology space.
"It's a pain point every single person has at some point in their lives, for themselves or for a family member or friend," said Curatio founder Lynda Ganzert-Brown. "It's a pain point every single person has at some point in their lives." There's also an AI concierge to answer questions about health information and a section for personal disease management and health tracking. So there are a lot of moving parts, especially when you consider that there are various different communities on Curatio: menopause, traumatic brain injury, heart disease, the blood disease Thalassemia, Crohn's disease and colitis, Type 1 diabetes, and a community for caregivers.